Equity Overview
Price & Market Data
Price: $0.96
Daily Change: -$0.0599 / 6.24%
Range: $0.90 - $1.05
Market Cap: $34,718,976
Volume: 164,088
Performance Metrics
1 Week: 14.78%
1 Month: -3.99%
3 Months: -18.64%
6 Months: 15.38%
1 Year: -9.86%
YTD: -20.00%
Details
Estrella Immunopharma, Inc., a clinical-stage biopharmaceutical company, develops T-cell therapies for blood cancers and solid tumors in the United States. The company's lead product candidates include EB103, which is in clinical trial, for the treatment of diffuse large B-cell lymphoma; EB104, which is in pre-clinical trial, to treat diffuse large B-cell lymphoma and acute lymphocytic leukemia; and EB201, which is in pre-clinical trial, for the treatment of systemic lupus erythematosus. It has a collaborative agreement with Eureka and Imugene Limited for the development of solid tumor treatments using Imugene's product candidate CF33-CD19t in conjunction with EB103. Estrella Immunopharma, Inc. was founded in 2006 and is headquartered in EmeryVille, California.